Non-pegylated liposomal doxorubicin plus capecitabine as first-line treatment in metastatic breast cancer
Journal Title: OncoReview - Year 2016, Vol 6, Issue 4
Abstract
Purpose: To determine the toxicity and efficacy profile of non-pegylated doxorubicin in combination with capecitabine administered according to LipAX regimen.
Authors and Affiliations
Piotr Plecka
Keywords
Related Articles
- EP ID EP186911
- DOI 10.5604/01.3001.0009.5068
- Views 206
- Downloads 0
Arterial hypertension related to sunitinib
Hypertension is a common concomitant disease in patients with renal carcinoma and a frequent complication of sunitinib therapy. Blocking of VEGF-dependent pathway leads to endothelial dysfunction, reduced nitric oxide pr...
Leczenie niedrobnokomórkowego raka płuca (NDRP) w stadium zaawansowania miejscowego lub rozsiewu w kontekście programu lekowego
W artykule przedstawiono aktualne zalecenia leczenia niedrobnokomórkowego raka płuca wobec ustaleń aktualnie obowiązującego programu lekowego.
Should a diagnosis of cancer impact the anticoagulant therapy in patients with recurrent thromboembolic disease?
Venous thromboembolism often coexists with cancer, deteriorating patient prognosis. The diagnosis of cancer in patients who suffer from venous thromboembolism may lead to changes in the anticoagulant therapy administered...
The role of vena cava inferior filters in the prevention of venous thromboembolism prior to oncological surgeries
Venous thromboembolism represents one of the most important causes of complications and mortality in cancer patients. The therapy in this group of patients is mainly focused on adequate anticoagulant prophylaxis. In diff...
Management strategy of patients with chronic myeloid leukemia in chronic phase who failed to response to imatinib – Kraków Haematology Clinic experience
Introduction: Tyrosine kinase inhibitors eliminate chronic myeloid leukemia cells in a targeted way. The resistance to this therapy was the cause of development of treatment recommendations and drugs of second and subseq...